Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘Synthetic Biology’

The audience of Biotech Strategy Blog is a broad “church” (no pun intended) of professionals associated with cancer drug development.

Oxford Bridge of Sighs

Bridge of Sighs, Oxford

Some readers with a research focus noticed I was in Oxford recently then contacted me to ask what scientific papers I was reading and catching up on over the lazy summer months?

This got me thinking as I was vividly reminded of my days as a PhD student at King’s College London, where the department would regularly meet to discuss key papers and recent research.

If your work has a narrow focus, and that applies to industry too, it’s sometimes difficult to see what’s on the horizon or be stimulated by ideas outside your immediate field, yet cross-fertilisation is an important pillar of learning. That’s one of the advantages of BSB, we cover a wide range of topics, at varying levels of complexity.

Welcome to the BSB Journal Club!

In this inaugural post, I’ve selected several recently published cancer immunotherapy papers that caught my attention, also a couple of books for your summer reading.

In case you worry that the science is above your ‘pay grade,’ for each I’ve written a brief summary and highlighted what data means from a commercial/new product development persepctive. You are of course most welcome to agree/disagree and reach your own conclusions… I hope it will stimulate your thinking.

Science often moves forward and develops as people make connections from a broader perspective.  I’m planning on running the “Journal Club” as a monthly ad hoc post to dovetail with the Reader Q&A Mailbag.

Subscribers can login or you can purchase access via the blue button below.

Dr Michel Sadelain AACR 2016

Dr Michel Sadelain at AACR 2016

Dr Michel Sadelain, Director of Cell Engineering at Memorial Sloan Kettering Cancer Center in New York is a pioneer in the field of adoptive cell therapy.

Without his contribution, it is unlikely CAR T cell therapy would be where it is today.

He’s also President of the American Society of Gene and Cell Therapy (ASGCT), whose annual meeting is currently underway in Washington DC from May 4 to 7 (Twitter #ASGCT16).

Recently at the annual meeting of the American Association for Cancer Research (AACR), Dr Sadelain gave an outstanding presentation on turbo-charged CAR T cells, and shared some of his ideas on how to move the field forward.

In New Orleans, he also kindly spoke to BSB, and discussed how he thinks cell therapy researchers may obtain the “holy grail” of getting CAR T cell therapies to work effectively in solid tumors.

Dr Sadelin is someone who wants to break the immunology rules!

Not surprisingly, Dr Sadelain is optimistic and doesn’t share the view expressed by Dr Steven Rosenberg on CAR T cell therapies being limited to mostly hematologic malignancies when we interviewed him a year ago at last year’s ASGCT meeting.  There’s nothing like a friendly controversy to spice the field up!

If you haven’t already done so, do listen to Dr Rosenberg on Episode 5 of the Novel Targets Podcast (@TargetsPodcast).

Subscribers can log-in or you can purchase access below to read more about what Dr Sadelain told BSB at AACR…

error: Content is protected !!